9/13/2013 8:35:36 AM
The latest twist in the prescription fish-oil saga emerged today when a federal appeals court issued a ruling that clears the way for generic versions of Lovaza, which has been a $1 billion seller for GlaxoSmithKline GSK +0.1% (here is the ruling). The news, however, was taken by some investors to be a big challenge for Amarin, a much-smaller player that sells the rival Vascepa pill.
Hey, check out all the research scientist jobs. Post your resume today!
comments powered by